RxDoctor Payments Data

Nnenna Okpara, MD

Gastroenterology · Providence, RINPI 1093813313

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 33.4% of the total. That places this record below the midpoint for gastroenterology clinicians in RI, where the typical reported total is $2,112.

$811in general payments, 2019–2025

Across 19 payments — averaging $42.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$271
  • AbbVie$237
  • Madrigal Pharmaceuticals$150
  • Pfizer$79
  • Redhill Biopharma Inc.$38
  • Medtronic$20
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$811 in reported general payments places this provider in the 35th percentile of 85 gastroenterology providers in Rhode Island.

See all gastroenterology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$16,606
Medicare patients
76
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$349,817
LinzessLinaclotide35$24,285
Omeprazole46$1,203
Famotidine36$590
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl28$440
Nadolol13$339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$271$349,81713 claims
AbbVieLinzess$237$24,28535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 85 gastroenterology providers in Rhode Island.

Other gastroenterology in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →